Intranasal self-administration of remifentanil as the foray into opioid abuse by an anesthesia resident.
Remifentanil is a potent micro-opioid receptor agonist that produces intense analgesia. This anilidopiperidine analog of fentanyl was approved by the United States Food and Drug Administration and became commercially available in the United States in 1997. Because of its unique chemical structure, remifentanil must be reconstituted; it has a rapid onset, and because of ester hydrolysis, it has a rapid rate of degradation. Although remifentanil's package insert warns against the potential for addiction, because of its rapid rate of degradation there was little concern that health care workers would abuse this drug. Herein, we report a case of intranasal remifentanil abuse by an anesthesiology resident.
Levine
Adam I
AI
Department of Anesthesiology, Mount Sinai Hospital, New York, New York 10029, USA.
Bryson
Ethan O
EO
D000281:Administration, Intranasal; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage; D000776:Anesthesiology / Q000193:education*; D005283:Fentanyl; D006801:Humans; D007396:Internship and Residency; D008297:Male; D010815:Physician Impairment; D010880:Piperidines / Q000008:administration & dosage; D000077208:Remifentanil; D019966:Substance-Related Disorders
D000701:Analgesics, Opioid; D010880:Piperidines; D000077208:Remifentanil; D005283:Fentanyl